Lumea and TreatmentGPS today announced the Alpine Path integration into Lumea’s software.
LEHI, UT, UNITED STATES, September 1, 2026 /EINPresswire.com/ — Lumea, a U.S. leader in digital pathology solutions, and TreatmentGPS, a physician-built AI platform for clinical decision support and patient education, today announced the Alpine Path integration into Lumea’s software. This integration enables guideline-based treatment guidance directly into the pathology reporting workflow.
When a urologist orders the test, Alpine Path reviews the pathology findings and generates a structured clinical summary aligned with current NCCN guidelines. The summary includes NCCN-based risk stratification, potential ancillary testing to consider, and treatment considerations based on the pathology findings, giving providers a concise reference alongside the pathologist’s original report. Alpine Path also produces a patient-friendly version of the report that translates medical terminology into plain language, helping patients understand their diagnosis, risk category, and treatment options.
“This integration reflects what we believe pathology reporting should do: connect a diagnosis to a clear, guideline-based next step, not just a result,” said James Thackeray, Lumea CEO.
Alpine Path is currently available for biopsy-related pathology reports covering prostate and bladder cancer, including metastatic prostate cancer cases. It can be enabled by default for a practice or ordered as an ancillary test following the pathology report.
For providers, Alpine Path is designed to save time and improve consistency: rather than manually cross-referencing lengthy pathology reports against current NCCN guidelines, providers receive a single summary covering key pathology findings, guideline-based risk categories, ancillary testing considerations, treatment considerations, and a patient-friendly educational summary, without adding work for the clinical team.
“Physicians and patients need clarity at the moment of diagnosis, not another system to log into. Alpine Path puts that guidance where the report already is,” said David S. DiMarco, MD, co-founder of TreatmentGPS and a practicing urologist.
Alpine Path was designed by practicing urologists who saw a need for clearer pathology reporting and more consistent application of evidence-based guidelines in everyday practice. By pairing provider-facing clinical decision support with patient-friendly education in a single report, Alpine Path aims to help ensure that every patient receives clear, evidence-based information, regardless of which provider they see.
Book a demo today to see how Alpine Path brings treatment guidance into the pathology report.
About Lumea
Lumea is advancing cancer diagnostics with a best-in-class Diagnostic Operating System (DxOS) built for modern pathology. By unifying the diagnostic ecosystem from tissue to treatment, Lumea enables laboratories and physicians to diagnose cancer with greater precision, speed, and confidence. A leader in U.S. digital pathology, Lumea is optimizing workflows, improving detection, and advancing more informed treatment decisions for patients. Learn more at lumeadigital.com.
About TreatmentGPS
TreatmentGPS is an AI-powered healthcare platform developed by physicians and engineers to improve clinical decision support, patient education, and practice intelligence across modern medical practices. By organizing complex clinical data and delivering guideline-based insights, TreatmentGPS simplifies workflows and helps care teams deliver more informed, more efficient care. TreatmentGPS is currently used and evaluated by leading urology practices across the United States, including Oregon Urology Institute, Minnesota Urology, and Urology Nevada. Learn more at treatmentgps.com.
Bianca Collings
Lumea
email us here
Visit us on social media:
LinkedIn
Instagram
YouTube
X
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Media gallery
